Biogen Idec Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2012; Provides Earnings Guidance for the Full Year 2013
For the year, the company reported net income attributable to the company of $1,380,033,000 or $5.76 per diluted share on total revenues of $5,516,461,000 compared to net income attributable to the company of $1,234,428,000 or $5.04 per diluted share on total revenues of $5,048,634,000 a year ago. Income from operations was $1,855,849,000 compared to $1,724,691,000 a year ago. Income before income tax expense and equity in loss of investee, net of tax was $1,855,105,000 compared to $1,711,214,000 a year ago. Net income was $1,380,033,000 compared to $1,266,686,000 a year ago. Non-GAAP net income attributable to the company was $1,566,600,000 or $6.53 per diluted share compared to $1,446,200,000 or $5.90 per diluted share a year ago.
The company provided earnings guidance for the full year 2013. For the period, the company's revenue growth is expected to be approximately 10%. Tax expense is expected to be approximately 24% to 26% of pretax income. Non-GAAP diluted EPS is expected to be between $7.15 and $7.25. GAAP diluted EPS is expected to be between $6.45 and $6.55. capital expenditures are expected to be in the range of $250 million to $270 million.